A Phase 3, Multicenter, Open-Label Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding
Latest Information Update: 16 May 2024
At a glance
- Drugs Levonorgestrel (Primary)
- Indications Menorrhagia
- Focus Therapeutic Use
- Sponsors Medicines360
Most Recent Events
- 25 Oct 2021 Status changed from active, no longer recruiting to completed.
- 28 Jan 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Aug 2021.
- 28 Jan 2021 Status changed from recruiting to active, no longer recruiting.